UK markets close in 51 minutes

NFL Biosciences SA (ALNFL.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
3.9000-0.0600 (-1.52%)
As of 12:47PM CEST. Market open.
Full screen
Previous close3.9600
Open3.9000
BidN/A x N/A
AskN/A x N/A
Day's range3.8200 - 3.9600
52-week range3.0000 - 5.0000
Volume1,399
Avg. volume12,228
Market cap20.415M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.90
  • Globe Newswire

    NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021

    NFL Biosciences: Availability of the Half Year Financial Report as of June 30, 2021 NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL a biopharmaceutical company developing botanical drugs for the treatment of addictions, announced today, Monday, October 4, 2021, that it has made available to the public and filed with the Autorité des Marchés Financiers (AMF) its Half Year Financial Report for the period ended June 30, 2021. The Half-Year Financial Report can be consulted on the comp

  • Globe Newswire

    NFL BIOSCIENCES: 2021 half-year financial and business report

    NFL Biosciences: 2021 half-year financial and business report Admission on Euronext Growth Paris: €5m raised from institutional, historical, and individual investors (July 2021) CESTO II Phase II/III clinical trial approved in Australia (May 2021) and France (September 2021) Clinical team strengthened NFL Bioscience’s patent issued in the US (September 2021) “Innovative company” qualification by BPIfrance recognized NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceuti

  • Globe Newswire

    NFL BIOSCIENCES: approval for its patent to be granted in the United States

    NFL BIOSCIENCES: approval for its patent to be granted in the United States NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that the United States Patent and Trademark Office (USPTO) issued, on September 21 with number US 11123395, the patent for NFL-101, a nicotine-free botanical drug candidate comprising natural proteins extracted from tobacco leaves, focused primarily on smoki